Loading clinical trials...

Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995 | Clinical Trials | Clareo Health

COMPLETED

Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995

NCT02116764•National Institute of Allergy and Infectious Diseases (NIAID)

Summary

This study is a longitudinal and cross-sectional evaluation of patients with Chronic Granulomatous Disease (CGD) who received or are receiving hematopoietic cell transplantation (HCT) for their disease under a variety of protocols used by participating institutions compared to a control non-HCT group receiving standard care. Investigators at multiple centers caring for patients with CGD in North America and 3 centers in Europe will participate. Patients with CGD will have been treated according to institutional practice and protocols. Investigators will enroll these patients as subjects in this protocol. This study will investigate which patients benefit most from HCT, and what types of transplants are optimal for patients with CGD, in the context of overall outcomes in CGD patients with and without transplant....

Detailed Description

Eligibility

Age

3 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Both HCT and non-HCT subjects must be over the age of 2 and actively enrolled and receiving treatment under a CGD protocol at NIAID.

Locations (1)

National Institutes of Health Clinical Center

Bethesda, Maryland, United States

Key Dates

Start Date

June 11, 2014

Primary Completion Date

June 2, 2022

Completion Date

June 2, 2022

Last Updated

March 20, 2026

Enrollment

137

ACTUAL participants

Conditions

Chronic Granulomatous Disease

Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists

NCT05463133

Chronic Granulomatous Disease

View study

RECRUITINGPHASE2

Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)

NCT07284641

Common Variable Immunodeficiency (CVID)Primary Immune Regulatory Disorder+13 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 20, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995

Inclusion Criteria

Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists

Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)

Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases

Study to Assess the Use of JSP191 in Matched Unrelated Donor Transplantation for Chronic Granulomatous Disease (CGD)

Genetic Disorders of Mucociliary Clearance in Nontuberculous Mycobacterial Lung Disease

Skin Immunity Sample Collection Involving Blisters and Biopsies